Skip to main content

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company believes, selectively suppresses only those immune cells involved in either an autoimmune process or rejection of tissue and organ transplants… It is this technology platform on which the company based the creation of the ADI(TM)-100 drug candidate, which is set to be evaluated in the planned clinical trials,” a recent article reads. “For the past two and a half years, acceleration of the ADI(TM) technology toward clinical trials has been a leading objective of Aditxt, and we now have reached a pivotal milestone by forming a subsidiary with its own dedicated team to advance the commercialization of one of our technologies – ADI(TM),” Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, is quoted saying.

To view the full article, visit https://ibn.fm/XC35M

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.